跳至主要内容
临床试验/NCT02468206
NCT02468206已完成不适用

Endoscopic Cyanoacrylate Injection vs. Balloon-occluded Retrograde Transvenous Obliteration in the Prevention of Gastric Variceal Rebleeding

West China Hospital1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2015年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
64
试验地点
1
主要终点
Rebleeding rate from gastric varices

研究概览

简要总结

The purpose of this study is to study the efficacy of endoscopic cyanoacrylate injection versus balloon-occluded retrograde transvenous obliteration in the prevention of gastric variceal rebleeding and improvement in survival.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who had bled from GOV2 or IGV1(≥5 days and ≤ 28days)
  • Presence of gastrorenal shunt

排除标准

  • Previous treatment of gastric varices, including endoscopic therapy, NSBB, TIPS, or surgery
  • Non-cirrhotic portal hypertension
  • Contraindications to cyanoacrylate injection or BRTO
  • Portal cavernoma
  • Hepatorenal syndrome
  • Proven malignancy including hepatocellular carcinoma
  • End-stage renal disease under renal replacement therapy;
  • Cardiorespiratory failure
  • Pregnancy or patients not giving informed consent for endoscopic procedures

研究组 & 干预措施

BRTO

Active Comparator

Balloon-occluded retrograde transvenous obliteration

干预措施: Balloon-occluded retrograde transvenous obliteration (Procedure)

BRTO

Active Comparator

Balloon-occluded retrograde transvenous obliteration

干预措施: Lauromacrogol (Drug)

NBCA

Active Comparator

Endoscopic Cyanoacrylate injection in the gastric varix

干预措施: Endoscopic cyanoacrylate injection (Procedure)

NBCA

Active Comparator

Endoscopic Cyanoacrylate injection in the gastric varix

干预措施: N-butyl-2-cyanoacrylate (Drug)

结局指标

主要结局

Rebleeding rate from gastric varices

时间窗: 3 years

次要结局

  • Number of participants with increase or decrease in the size of gastric varices(3 years)
  • Number of participants with appearance or worsening of new oesophageal varices(3 years)
  • Eradication rate of gastric varices(3 years)
  • Cost of treatment(3 years)
  • Number of participants with appearance or worsening of ascites(3 years)
  • Number of participants with complication(3 years)
  • Average in-hospital stay(3 years)
  • Mortality rate(3 years)
  • Number of participants with appearance or worsening of portal hypertensive gastropathy(3 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

luo xuefeng

MD

West China Hospital

研究点 (1)

Loading locations...

相似试验